Mavorixafor

Generic Name: Mavorixafor

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₇N_₅

CAS Number: 558447-26-0

Unique Ingredient Identifier: 0G9LGB5O2W

Background: Mavorixafor is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Currently there is only one FDA-approved entry inhibitor, enfuvirtide (Fuzeon), that is available for the treatment of HIV infection. Several experimental entry inhibitors are now in early stage testing, including mavorixafor. Mavorixafor is a selective allosteric antagonist of the CXCR4 receptor on HIV, preventing the virus from entering and infecting healthy cells.

Indication: Investigated for use/treatment in HIV infection.

Clinical Trials

Drug-Drug Interaction Potential of Mavorixafor

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Mavorixafor
Drug: Carbamazepine
Drug: Efavirenz

First Posted Date: 2025-04-06

Last Posted Date: 2025-04-06

Lead Sponsor: X4 Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT06914869

Locations: 🇺🇸
Parexel International LLC, Baltimore, Maryland, United States

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Phase 1

Recruiting

Conditions: Hepatic Insufficiency

Interventions: Drug: Mavorixafor

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-03

Lead Sponsor: X4 Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT06858696

Locations: 🇺🇸
Catalina Research Institute, LLC, Rialto, California, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Texas Liver Institute/Alamo Medical Research, San Antonio, Texas, United States

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Phase 3

Recruiting

Conditions: Neutropenia

Interventions: Drug: Mavorixafor
Drug: Placebo

First Posted Date: 2023-09-28

Last Posted Date: 2025-04-17

Lead Sponsor: X4 Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT06056297

Locations: 🇩🇪
Universitaetsklinikum Carl Gustav Carus Tu Dresden, Dresden, Germany
🇬🇷
Hellenic Airforce 251 General Hospital, Athens, Greece
🇬🇷
University General Hospital of Heraklion, Iraklio, Greece

and more 75 locations

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Phase 1

Conditions: Triple Negative Breast Cancer

Interventions: Drug: X4P-001

First Posted Date: 2021-11-02

Last Posted Date: 2021-11-02

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 24

Registration Number: NCT05103917

Locations: 🇨🇳
Shang hai Tumor Hospital, Shanghai, Shang Hai, China

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Phase 1

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Mavorixafor
Drug: Ibrutinib

First Posted Date: 2020-02-18

Last Posted Date: 2024-08-27

Lead Sponsor: X4 Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT04274738

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Mass General Hospital Cancer Center, Boston, Massachusetts, United States
🇬🇷
University of Athens, Athens, Greece

and more 2 locations

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Phase 1

Completed

Conditions: Neutropenia

Interventions: Drug: Mavorixafor

First Posted Date: 2019-11-06

Last Posted Date: 2024-11-15

Lead Sponsor: X4 Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT04154488

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
USF Health Department of Pediatrics, Saint Petersburg, Florida, United States

and more 4 locations

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Phase 3

Active, not recruiting

Conditions: WHIM Syndrome

Interventions: Drug: Mavorixafor
Drug: Placebo

First Posted Date: 2019-06-21

Last Posted Date: 2024-05-02

Lead Sponsor: X4 Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT03995108

Locations: 🇦🇺
Wesley Hospital, Auchenflower, Queensland, Australia
🇭🇺
University of Debrecen, Affiliated Department of Infectology, Debrecen, Hajdu-Bihar, Hungary
🇫🇷
CHU de Lyon, Institut d'Hematologie et d'Oncologie Pediatrique, Lyon, Rhne, France

and more 20 locations